GCC Obesity & Bariatric Nursing Guide

BMI Classification (WHO Standard)

Category	BMI (kg/m²)	Clinical Implication
Underweight	< 18.5	Nutritional deficiency risk, frailty
Normal weight	18.5 – 24.9	Target range for most adults
Overweight	25.0 – 29.9	Lifestyle intervention recommended
Obese Class I	30.0 – 34.9	Moderate comorbidity risk
Obese Class II	35.0 – 39.9	High risk; consider pharmacotherapy
Obese Class III (Severe)	≥ 40.0	Very high risk; bariatric surgery eligible

GCC/South Asian Adjusted Cut-Offs: Overweight ≥ 23 kg/m², Obese ≥ 27.5 kg/m² — Intervention thresholds lower due to higher visceral fat and cardiometabolic risk at lower BMI values in Asian populations.

Waist Circumference

South Asian / GCC Ethnic Thresholds

Sex	Risk Threshold
Men	> 90 cm (abdominal obesity)
Women	> 80 cm (abdominal obesity)

Waist circumference is a better predictor of metabolic risk than BMI alone. Measure at the midpoint between the lowest rib and iliac crest with the patient standing and at end expiration.

Visceral vs Subcutaneous Fat

Visceral fat: surrounds organs; strongly linked to insulin resistance, T2DM, CVD, and inflammation; cannot be palpated
Subcutaneous fat: beneath skin; metabolically less harmful; responds well to exercise
GCC patients often have high visceral fat with lower BMI — waist:height ratio >0.5 is a red flag

Edmonton Obesity Staging System

Stage	Description
Stage 0	No risk factors, no physical/psychological symptoms
Stage 1	Subclinical risk factors (pre-HTN, impaired fasting glucose)
Stage 2	Established comorbidities (T2DM, HTN, sleep apnoea, OA)
Stage 3	Significant organ damage, major functional impairment
Stage 4	Severe/end-stage disease, extreme functional limitation

EOSS is superior to BMI alone for guiding treatment intensity. Stage 2+ warrants active medical or surgical intervention.

ABCD Framework — Adiposity-Based Chronic Disease

A — Anthropometric

BMI, waist circumference, waist:hip ratio, bioimpedance body fat %, DEXA scan fat mass

B — Biochemical/Clinical

Fasting glucose, HbA1c, lipid profile, liver enzymes (NAFLD), uric acid, CRP, insulin

C — Complications

Identify obesity-driven complications: cardiometabolic, mechanical, psychosocial

D — Driver Analysis

Genetic factors, medications (antipsychotics, steroids), hypothyroidism, sleep disorders, stress, socioeconomic

Obesity Complications Mapping

Cardiovascular

HTN, heart failure, dyslipidaemia, AF, stroke risk

Metabolic

Type 2 diabetes, insulin resistance, NAFLD/NASH, metabolic syndrome

Respiratory

Obstructive sleep apnoea, obesity hypoventilation syndrome, asthma

Musculoskeletal

Osteoarthritis (knees/hips), low back pain, gout, chronic pain

Reproductive

PCOS, infertility, erectile dysfunction, pregnancy complications

Cancer

Endometrial, breast, colon, oesophageal, kidney, liver cancer risk elevated

Gastrointestinal

GORD, gallstones, NAFLD progressing to cirrhosis

Psychological

Depression, anxiety, eating disorders (BED), poor self-esteem, social isolation

Genitourinary

Stress urinary incontinence, chronic kidney disease progression

BMI & Weight Classification Calculator

Height (cm)

Weight (kg)

Ethnicity

Your BMI

Lifestyle Interventions

Structured Weight Management

Target: 5–10% body weight loss achieves significant metabolic benefit
≥10% loss may lead to T2DM remission and NAFLD regression
VLCD: 400–800 kcal/day (meal replacement, supervised, max 12 weeks)
LCD: 800–1,200 kcal/day (flexible food-based approach)
Low-fat OR low-carbohydrate diets are both effective — adherence is key
Mediterranean diet: evidence-based, culturally adaptable for GCC

Physical Activity Guidelines

150–300 min/week moderate-intensity aerobic (brisk walking, swimming)
Resistance training: 2× per week — preserves lean muscle during weight loss
High temperatures in GCC: advise indoor or early morning/evening activity
For severe obesity: start with 10-min bouts, chair-based or aquatic exercise
Pedometer/app-based self-monitoring improves adherence

Behavioural Interventions

CBT for Weight Loss

Identifies cognitive distortions around food; addresses emotional eating triggers; restructures maladaptive beliefs

Motivational Interviewing

Patient-centred approach exploring ambivalence; OARS technique (Open questions, Affirmations, Reflections, Summaries)

Self-Monitoring

Food diary, calorie tracking apps, wearable activity trackers — strongest behavioural predictor of long-term success

Pharmacotherapy for Obesity

Orlistat (Xenical / Alli)

Mechanism: pancreatic lipase inhibitor — blocks 30% dietary fat absorption
Dose: 120mg with each main meal (prescription); 60mg OTC
Efficacy: ~3–4 kg additional weight loss vs placebo
GI side effects: oily stools, faecal urgency, steatorrhoea — particularly with high-fat meals
Nurse counselling: low-fat diet compliance is essential; take fat-soluble vitamins (A/D/E/K) 2h before or after
Contraindicated in cholestasis, malabsorption syndromes

GLP-1 Receptor Agonists

Drug	Dose/Route	Weight Loss	Key Notes
Semaglutide (Wegovy)	2.4 mg SC weekly	~15% (STEP trials)	Gold standard; dose escalation over 16 weeks
Liraglutide (Saxenda)	3.0 mg SC daily	~8–9%	Daily injection; older agent
Tirzepatide (Mounjaro/Zepbound)	Up to 15mg SC weekly	~20–22% (SURMOUNT)	Dual GIP/GLP-1; superior efficacy

Nursing Points for GLP-1 Agonists

Injection Technique

Rotate sites: abdomen, thigh, upper arm
Allow pen to reach room temperature (30 min)
90° angle, slow injection, hold 10 seconds
Store unused pens in fridge (2–8°C)

Side Effect Management

Nausea (most common): small meals, avoid fatty/spicy food, ginger
Vomiting: ensure hydration, reduce dose if severe
Constipation: increase fluids and fibre
Start low, go slow — dose escalation is critical

PANCREATITIS WARNING: Educate patients to seek immediate care if severe, persistent upper abdominal pain radiates to the back. Contraindicated with personal/family history of MEN2 or medullary thyroid carcinoma.

GCC Nurse-Led Obesity Clinics: Nurses in GCC are increasingly leading tier 2 and tier 3 obesity services — prescribing under PGD (Patient Group Directions), motivational counselling, injection training, and long-term follow-up. HAAD/MOH nursing frameworks support this expanding scope.

Indications for Bariatric Surgery

Standard Criteria

BMI ≥ 40 kg/m² (Class III obesity)
BMI ≥ 35 kg/m² with one or more obesity-related comorbidity (T2DM, HTN, sleep apnoea, OA)
Failed ≥ 6 months of supervised conservative management
Psychologically motivated and informed
Age 18–65 (case-by-case outside range)

Contraindications

Active substance misuse or alcohol dependency
Uncontrolled psychiatric illness
Non-compliance with pre-operative programme
Active malignancy
Portal hypertension / liver cirrhosis (relative)
Severe cardiac/pulmonary disease (relative)

GCC-adjusted: BMI ≥ 35 or ≥ 30 with T2DM in Asian patients may qualify per IFSO Asian guidelines.

Types of Bariatric Surgery

Sleeve Gastrectomy (SG) — Most Common in GCC

80% of stomach removed, creating a sleeve/tube shape
Mechanism: restrictive (smaller stomach volume) + hormonal (reduces ghrelin)
Expected weight loss: 60–70% excess weight loss at 2 years
Advantages: no bowel rerouting, shorter operative time, no band hardware
Disadvantage: GORD may worsen significantly post-operatively

Roux-en-Y Gastric Bypass (RYGB) — Gold Standard for T2DM Remission

Small gastric pouch (~30 mL) + small intestine bypass (Roux limb)
Mechanism: restrictive + malabsorptive + hormonal (GLP-1 surge)
T2DM remission: 80–85% at 2 years — often before significant weight loss
Expected weight loss: 70–80% EWL at 2 years
Higher nutritional deficiency risk — lifelong supplementation mandatory

Adjustable Gastric Band (AGB) — Declining in Use

Silicone band placed around upper stomach, adjusted via port
Purely restrictive; lowest complication rate short-term
Poor long-term outcomes; high revision rate; band slippage risk
Being phased out in most GCC centres

Biliopancreatic Diversion with Duodenal Switch (BPD/DS)

Sleeve gastrectomy + significant small bowel bypass
Highest weight loss (80–90% EWL) and strongest T2DM remission
Highest nutritional deficiency risk — intensive monitoring required
Reserved for BMI > 50 or failed previous bariatric surgery

Pre-Operative Requirements

Multidisciplinary Team

Bariatric surgeon
Endocrinologist/physician
Bariatric nurse specialist
Dietitian
Psychologist/psychiatrist
Anaesthesiologist
Physiotherapist

Clinical Assessments

Nutritional assessment (B12, iron, folate, VitD, thiamine)
Psychological evaluation (eating behaviours, BMI history, support)
Sleep study (polysomnography — OSA prevalence >50% in surgical candidates)
Cardiac risk assessment (ECG, echo if indicated)
Upper GI endoscopy (H.pylori screen — mandatory in many GCC centres)
Pulmonary function tests if indicated

Pre-Op Liver Reduction

2–4 week low-calorie / VLCD diet pre-operatively
Reduces liver size by 20–30% — improves surgical access
Improves intra-operative safety
800–1000 kcal/day milk-based or meal replacement
Compliance checked by surgeon — non-compliance may delay surgery

Post-Operative Dietary Progression

Phase	Timeframe	Diet	Nursing Points
Clear fluids	Day 1–2	Water sips 30–60 mL/hr, dilute juice, broth	Assess swallow; monitor for leak signs
Full liquids	Days 2–14	Protein shakes, milk, yoghurt drink, soup	60–80g protein/day target; 1500 mL fluid minimum
Pureed foods	Weeks 2–4	Smooth puréed proteins: eggs, fish, lentils, soft tofu	No lumps; eat slowly, 20–30 min/meal
Soft foods	Weeks 4–6	Soft proteins, cooked vegetables, soft fruit	Stop eating at first satiety signal
Normal foods	Week 8+	Gradual texture introduction; small portions	No carbonated drinks, no straws, no NSAIDS

General Rules: Eat slowly (20–30 min/meal), chew thoroughly (20–30 chews), avoid drinking 30 minutes before/after eating, no fizzy drinks ever, portion size 100–200 mL initially.

Mandatory Lifelong Nutritional Supplementation

Supplement	Dose	Notes
Multivitamin	1–2 daily (chewable initially)	Bariatric-specific formulation preferred
Calcium citrate	1,200–1,500 mg/day in divided doses	Citrate preferred over carbonate (better absorption without acid)
Vitamin D	3,000 IU/day (minimum)	Monitor serum 25-OH-VitD; target >75 nmol/L
Vitamin B12	1,000 mcg/month IM or 1,000 mcg/day oral sublingual	Essential post-RYGB/sleeve; oral high-dose effective if sublingual/IM unavailable
Iron	45–60 mg elemental iron/day	Especially premenopausal women; take with vitamin C
Thiamine (B1)	Supplement all BYPASS patients	Critical post-RYGB; deficiency causes Wernicke's encephalopathy

Monitoring Schedule

3 months: FBC, ferritin, B12, folate, VitD, calcium, albumin, glucose
6 months: Full panel + lipid profile, LFTs, HbA1c
Annual: All above + PTH, zinc, copper, selenium (post-RYGB/BPD)
DEXA scan: at 2 years post-op for bone density baseline

Protein target: minimum 60–80 g/day. Prioritise protein at every meal. Inadequate protein leads to muscle mass loss, hair loss (telogen effluvium — peaks 3–6 months post-op, reassure patient), and poor wound healing.

Dumping Syndrome

Early Dumping (15–30 min post-meal)

Mechanism: rapid gastric emptying → osmotic fluid shift into bowel

Symptoms: bloating, cramping, diarrhoea, nausea, palpitations, flushing, sweating
Management: small frequent meals (5–6/day), avoid simple sugars, liquid separation from food, lie down after eating, high-protein low-GI meals

Late Dumping (1–3 hours post-meal)

Mechanism: rapid carbohydrate absorption → insulin surge → hypoglycaemia

Symptoms: weakness, tremor, sweating, confusion, palpitations — similar to hypoglycaemia
Management: low GI diet, avoid simple sugars, complex carbs only, check BM if symptomatic, acarbose if refractory

If hypoglycaemia is confirmed (BM <3.5 mmol/L), treat as per hypoglycaemia protocol. Avoid sugary drinks/juice as first-line — preference for 15g glucose tablets to avoid rebound. Refer for dietitian review.

Post-Bariatric Protein Tracker

Surgery Type

Time Since Surgery

Estimated Daily Protein Intake (grams)

Early Post-Operative Complications

Anastomotic / Staple Line Leak — SURGICAL EMERGENCY

Classic presentation: Tachycardia (>120 bpm) + Tachypnoea + Shoulder tip pain / left upper quadrant pain (2–7 days post-op). Can present without fever. HIGH clinical suspicion required — do not dismiss as normal post-op discomfort.

Incidence: 1–3% sleeve, 1–2% RYGB
Investigations: CT abdomen/pelvis with oral contrast (water-soluble Gastrografin) is gold standard; upper GI series; CRP/WCC rise
Management: NBM, IV antibiotics, surgical review, possible re-exploration, percutaneous drain or endoscopic stent
Nursing: report tachycardia >100 even without fever; escalate urgently; prepare for CT

Staple Line Haemorrhage

Presentation: haematemesis, melaena, haematochezia, tachycardia, hypotension
Investigations: urgent FBC, cross-match, upper GI endoscopy
Management: resuscitation, endoscopic haemostasis, surgical re-exploration if refractory

Late Post-Operative Complications

GORD Post-Sleeve Gastrectomy

GORD worsens in up to 30% after sleeve — due to reduced gastric compliance and changed anatomy
Management: high-dose PPI, lifestyle modification, head-of-bed elevation
Persistent/severe GORD post-sleeve: may require conversion to RYGB (RYGB is actually protective against GORD)
Nurse counselling: never stop PPI without surgical team advice post-sleeve

Internal Hernia (Post-RYGB) — SURGICAL EMERGENCY

Bowel herniation through mesenteric defect created at surgery
Presentation: intermittent, crampy central abdominal pain; may worsen with eating; often no peritonism
Investigations: CT abdomen (may be normal between episodes); high clinical suspicion required
Management: urgent surgical repair — risk of bowel ischaemia/strangulation

Marginal Ulcer

Occurs at gastrojejunal anastomosis post-RYGB; incidence 1–16%
Risk factors: H.pylori infection, NSAIDs, smoking, alcohol, foreign material (staples)
Presentation: epigastric pain, nausea, upper GI bleed
Management: test and treat H.pylori, high-dose PPI (omeprazole 40mg BD), strict NSAID avoidance, smoking cessation

Nutritional Deficiency Complications

Vitamin B12 Deficiency

Symptoms: peripheral neuropathy, subacute combined degeneration, glossitis, fatigue, macrocytic anaemia
Screen: B12 level at every follow-up
Treat: IM B12 1000mcg/month or daily sublingual 1000mcg

Iron Deficiency Anaemia

Most common deficiency post-bariatric; especially in menstruating women
Symptoms: fatigue, pallor, palpitations, restless legs, pica
Screen: ferritin, serum iron, TIBC
Treat: oral iron + Vit C; IV iron if refractory

Calcium & Vitamin D

Long-term leads to metabolic bone disease (secondary hyperparathyroidism, osteoporosis, stress fractures)
Monitor: serum calcium, 25-OH-VitD, PTH, ALP
DEXA scan: baseline at 2 years; annually if abnormal
Calcium citrate preferred post-bypass (absorbed without gastric acid)

Thiamine (B1) deficiency: risk in early post-op persistent vomiting. Presents as Wernicke's encephalopathy (confusion + ophthalmoplegia + ataxia) — IV thiamine 200mg TDS immediately if suspected. DO NOT give glucose before thiamine in thiamine-deficient states.

Country	Centre
Saudi Arabia	KFMC Riyadh, King Fahad Hospital Jeddah, NGHA
UAE	American Hospital Dubai, Medcare Hospital, NMC Healthcare
Qatar	HMC Weight Management Centre, Hamad General Hospital
Kuwait	Al-Amiri Hospital, Mubarak Al-Kabeer Hospital
Bahrain	BDF Hospital, Bahrain Specialist Hospital